MYRBETRIQ®

Hold Company

Astellas Pharma US, Inc

Learn More

Dosage and Administration

TABLET, EXTENDED RELEASE;ORAL

Specification

25MG; 50MG

Indication

MYRBETRIQ® is indicated for adults with overactive bladder (OAB) and children with neurogenic detrusor overactivity (NDO).

Use

Instructions for Use

API

MIRABEGRON

API Structure

We Supply

MIRABEGRON

Note:

USP/In-house Standard/CP
Facility GMP
USMF/DMF/WC/ASMF/KDMF

Drug Patent

Patent No	Expiration Date
10842780	2029/9/28
10842780*PED	2030/3/28
11707451	2029/9/28
11707451*PED	2030/3/28
7342117	2023/11/4
7342117*PED	2024/5/4
7982049	2023/11/4
7982049*PED	2024/5/4
8772315	2028/10/30
8772315*PED	2029/4/30
8835474	2023/11/4
8835474*PED	2024/5/4
RE44872	2023/11/4
RE44872*PED	2024/5/4

API Patent

Patent No	Expiration Date
7342117	2023/11/4
7342117*PED	2024/5/4
7982049	2023/11/4
7982049*PED	2024/5/4

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.